On 3 February 2022 the UK antitrust watchdog, the Competition and Markets Authority (CMA), fined several pharmaceutical companies over 35 million pounds for an illegal arrangement in the supply of important National Health Service (NHS) prescription anti-nausea tablets, namely prochlorperazine 3mg dissolvable or ‘buccal’ tablets.^[1]Press release of the CMA of 3 February 2022, ‘CMA fines firms over £35m for illegal arrangement for NHS drug’. Under the arrangement, a competitor was paid not to launch a product and price increases were enabled. From 2013 to 2017, the prices paid by the NHS for prochlorperazine increased by 700%. The CMA found that, from June 2013 to July 2018, Alliance Pharmaceuticals, Focus Pharmaceuticals (now owned by ADVANZ PHARMA Corp., previously owned by the private equity firm Cinven Ltd), and Lexon UK ^[2]The infringement decision is addressed to the following legal entities: (i) Alliance Pharmaceuticals Ltd and Alliance Pharma plc; (ii) Focus Pharmaceuticals Ltd, Focus Pharma Holdings Ltd, Mercury … Continue reading were involved in the arrangement. Another company (Medreich plc) was involved in the arrangement between February 2014 and February 2018. Alliance Pharmaceuticals Ltd is appealing the CMA’s fine decision.